Physician profile
Husain Arastu
NPI 1528017555
$1,684.17
in general payments reported to CMS, 2019-2025
10 companies · $279 in 2025
The $279 reported for 2025 was more than what 82% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $17.65 · 2021: $283 · 2022: $306 · 2023: $419 · 2024: $148 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $549.35 | 2019-2025 | Penmenvy, Bexsero, Pediarix |
| Corium, LLC | $519.83 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $245.23 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $210.03 | 2021-2025 | Qelbree, Qelbree |
| Cipher Pharmaceuticals US LLC | $44.29 | 2025 | Spinosad, Natroba |
| Tris Pharma INC | $31.14 | 2025 | Dyanavel Xr |
| Cranial Technologies, INC | $30.66 | 2022-2023 | Doc Band |
| Amneal Pharmaceuticals LLC | $27.88 | 2019 | |
| Merck Sharp & Dohme LLC | $13.90 | 2019 | |
| Pfizer INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husain Arastu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.